Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

FibroGen Q2 EPS $(1.88) Beats $(2.25) Estimate, Sales $1.35M Miss $2.63M Estimate

Author: Benzinga Newsdesk | August 11, 2025 04:22pm
FibroGen (NASDAQ:FGEN) reported quarterly losses of $(1.88) per share which beat the analyst consensus estimate of $(2.25) by 16.44 percent. This is a 53 percent increase over losses of $(4.00) per share from the same period last year. The company reported quarterly sales of $1.35 million which missed the analyst consensus estimate of $2.63 million by 48.75 percent. This is a 97.34 percent decrease over sales of $50.64 million the same period last year.

Posted In: FGEN


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist